-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673

Benzinga·09/30/2026 16:01:25
Listen to the news
UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.